Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.

TypePublic
HQStamford, US
Founded2013
Size (employees)47 (est)+57%
Websiteloxooncology.com
Loxo Oncology was founded in 2013 and is headquartered in Stamford, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Loxo Oncology Office Locations

Loxo Oncology has offices in Stamford and South San Francisco
Stamford, (HQ)
281 Tresser Blvd
South San Francisco,
520 400 Oyster Point Blvd
Show all (2)
Report incorrect company information

Loxo Oncology Financials and Metrics

Loxo Oncology Revenue

USD

Net income (Q2, 2018)

(15.3m)

EBIT (Q2, 2018)

(20.5m)

Market capitalization (4-Dec-2018)

4.1b

Closing stock price (4-Dec-2018)

133.5

Cash (30-Jun-2018)

147.7m
Loxo Oncology's current market capitalization is $4.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

583.0k10.5m14.9m33.7m

R&D expense

323.0k14.0m58.3m140.0m

Operating expense total

906.0k24.5m73.2m173.7m

EBIT

(152.4m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.4m2.6m3.4m3.8m3.7m4.8m6.5m9.7m12.2m27.9m

R&D expense

2.8m3.4m8.4m12.3m14.2m20.2m24.4m64.8m32.0m73.5m

Operating expense total

5.2m5.9m11.8m16.1m17.9m24.9m30.9m74.4m44.2m101.5m

EBIT

(5.8m)(20.5m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

43.9m68.2m30.4m142.0m

Accounts Receivable

1.1b

Current Assets

107.8m156.6m141.8m781.8m

PP&E

12.0k88.0k248.0k912.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(20.7m)(35.9m)(72.4m)(148.9m)

Depreciation and Amortization

1.0k17.0k77.0k125.0k

Accounts Payable

18.0k30.0k792.0k2.9m

Cash From Operating Activities

(2.8m)(30.2m)(51.3m)107.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(8.1m)(8.8m)(11.6m)(15.9m)(17.7m)(24.5m)(54.9m)(128.2m)(3.6m)(15.3m)

Depreciation and Amortization

21.0k48.0k80.0k80.0k186.0k

Accounts Payable

207.0k285.0k415.0k731.0k758.0k677.0k1.0m192.0k1.1m768.0k1.8m793.0k

Cash From Operating Activities

(26.7m)(50.5m)(113.4m)109.8m74.8m
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information

Loxo Oncology Online and Social Media Presence

Embed Graph
Report incorrect company information

Loxo Oncology News and Updates

Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress

- Median Duration of Response Not Reached With One Year of Additional Follow-up -

Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer

STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy D…

Loxo Oncology Announces Accepted Abstracts at the 88th Annual Meeting of the American Thyroid Association

STAMFORD, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that abstracts from its LOXO-292 and larotrectinib programs have been accepted for…

Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292

STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy …

Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer

STAMFORD, Conn., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that abstracts from its LOXO-292 and larotrectinib programs have been accepted for …
Show more
Report incorrect company information

Loxo Oncology Company Life and Culture

Report incorrect company information

Loxo Oncology Frequently Asked Questions

  • When was Loxo Oncology founded?

    Loxo Oncology was founded in 2013.

  • How many employees does Loxo Oncology have?

    Loxo Oncology has 47 employees.

  • Who are Loxo Oncology competitors?

    Competitors of Loxo Oncology include Keryx Biopharmaceuticals, NovaBay Pharmaceuticals and Chiasma.

  • Where is Loxo Oncology headquarters?

    Loxo Oncology headquarters is located at 281 Tresser Blvd, Stamford.

  • Where are Loxo Oncology offices?

    Loxo Oncology has offices in Stamford and South San Francisco.

  • How many offices does Loxo Oncology have?

    Loxo Oncology has 2 offices.